BIAL - Portela & Ca., S.A.
Category(ies): Healthcare Providers; Pharmaceutical Companies; R&D Institutions
Address: À Avenida da Siderurgia Nacional; 4745-457 Coronado (S. Romão e S. Mamede); Portugal
Keyword(s): Cardiovascular System, Central Nervous System, Health, Pharmaceuticals, Research & Development
Founded in 1924, BIAL’s mission is to discover, develop and provide therapeutic solutions within the area of health. Being the largest Portuguese pharmaceutical company, BIAL has a strong presence in the Iberian Peninsula as well as in countries in Latin America and French or Portuguese speaking African countries. In recent decades, BIAL has focused on quality, innovation and internationalization. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its turnover in research and development (R&D) every year, placing it among the most innovative European companies. Key research areas for BIAL are the central nervous system, the cardiovascular system and allergen immunotherapy. BIAL Group has launched the first drug of Portuguese patent, an anti-epileptic, already available in the US market and in several European countries. The second pharmaceutical of its own research (Opicapone), for the treatment of the Parkinson disease, is already under review by the European Medicines Agency (EMA). With a team of 900 employees, the company expects to introduce more new medicines and vaccines to the market in the next years and reinforce its international presence. Bial Group has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award and Scientific Research Grants, well recognized worldwide.
+351 229 866 100
+351 229 866 190
International Medical Affairs Manager (M/F)